NAC Supplement Guide: Glutathione, Liver Health, and Lung Support

N-Acetyl Cysteine: From Hospital Antidote to Everyday Supplement

N-acetyl cysteine (NAC) occupies a unique position in pharmacology and nutrition. It is simultaneously a standard hospital medicine — administered intravenously as the antidote for paracetamol (acetaminophen) overdose and used as a mucolytic in acute respiratory conditions — and a widely available food supplement with an expanding body of evidence for its effects on oxidative stress, immune function, and mental health. This dual existence reflects the depth of evidence that underpins it.

NAC as a Glutathione Precursor

Glutathione is the body's primary endogenous antioxidant. It is a tripeptide composed of glutamine, glycine, and cysteine. Of these three components, cysteine is the rate-limiting precursor — intracellular cysteine availability largely determines the rate at which cells can synthesise glutathione.

NAC is a stable, well-absorbed cysteine derivative. Following absorption from the gut, it is deacetylated to cysteine in the cells, rapidly driving glutathione synthesis. Taking glutathione directly as a supplement is largely ineffective for raising intracellular levels because it is poorly absorbed intact; NAC bypasses this limitation by providing the precursor.

Liver Protection: The Hospital Evidence

NAC's role as the antidote for paracetamol hepatotoxicity is the best-established clinical application. Paracetamol overdose saturates the liver's normal sulfation and glucuronidation pathways, causing accumulation of the toxic metabolite NAPQI, which depletes hepatic glutathione and causes necrosis. Intravenous NAC replenishes glutathione rapidly and — if administered within 8–10 hours of ingestion — prevents liver damage with near-complete efficacy. Even after this window, NAC reduces the severity of hepatic injury.

This is not merely a theoretical application — it is standard NHS emergency protocol. The evidence for this mechanism is ironclad, and by extension, NAC's role in supporting hepatic glutathione pools is one of its most mechanistically validated properties.

For non-emergency contexts, there is also evidence from trials in patients with non-alcoholic fatty liver disease (NAFLD) that oral NAC reduces liver enzyme levels (ALT, AST) over 12–24 weeks, consistent with reduced oxidative stress in hepatic tissue.

Mucolytic Effects in Lung Conditions

NAC thins mucus by breaking the disulfide bonds between mucin polymers, reducing mucus viscosity. This mucolytic property is the basis for its use in hospitals for acute respiratory conditions including COPD exacerbations, cystic fibrosis, and bronchiectasis. It is available on prescription in the UK as carbocisteine or acetylcysteine for these indications.

Meta-analyses of NAC supplementation in COPD patients show modest reductions in exacerbation frequency. A 2014 Cochrane review found evidence that NAC reduced the frequency of COPD exacerbations in patients not receiving inhaled steroids.

Mental Health: Emerging but Promising Evidence

The most actively investigated emerging application for NAC is in mental health, where it is being studied as an adjunct to conventional treatment for several conditions. The rationale is mechanistic: oxidative stress and glutathione depletion are implicated in the pathophysiology of depression, OCD, bipolar disorder, and schizophrenia.

NAC has the most evidence in OCD, where several controlled trials have shown benefit as an add-on therapy at 600–3000 mg per day. A 2012 randomised trial by Sarris et al. found significant reductions in OCD symptom scores with 3 g NAC per day over 16 weeks. Evidence in depression is supportive but less consistent. Trials in bipolar disorder suggest NAC may reduce depressive episodes rather than manic ones.

This evidence is not sufficient to position NAC as a primary mental health treatment, but the safety profile and mechanistic rationale make it a reasonable consideration for adjunct use under medical supervision.

Dosing and Safety

For general supplementation, 600–1200 mg per day is the standard dose range, typically divided into two doses. For specific clinical applications (OCD, liver support), doses up to 2400–3000 mg have been used in trials. NAC is generally well-tolerated. At high doses, gastrointestinal discomfort (nausea, diarrhoea) can occur. There is a theoretical concern about NAC reducing the efficacy of certain chemotherapy drugs — individuals receiving cancer treatment should avoid supplementation without oncologist guidance.

Pregnancy caution: NAC is being investigated in trials for pregnancy complications, but the evidence for routine supplementation in pregnancy is insufficient and it should be avoided outside supervised clinical settings.